{"name":"CanSino Biologics Inc.","slug":"cansino-biologics-inc","ticker":"","exchange":"","domain":"cansinobiologics.com","description":"","hq":"Tianjin","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"ChAdOx1-VZV","genericName":"ChAdOx1-VZV","slug":"chadox1-vzv","indication":"Other","status":"phase_1"},{"name":"DTcP","genericName":"DTcP","slug":"dtcp","indication":"Prevention of diphtheria, tetanus, and pertussis in pediatric and adult populations","status":"phase_3"},{"name":"MCV4","genericName":"MCV4","slug":"mcv4","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y","status":"marketed"},{"name":"MPSV4","genericName":"MPSV4","slug":"mpsv4","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y","status":"phase_3"},{"name":"MSPV4","genericName":"MSPV4","slug":"mspv4","indication":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y","status":"phase_3"},{"name":"Placebo for Inhalation","genericName":"Placebo for Inhalation","slug":"placebo-for-inhalation","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"PCV13i","genericName":"PCV13i","slug":"pcv13i","indication":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F","status":"phase_3"},{"name":"TT","genericName":"TT","slug":"tt","indication":"COVID-19 prevention (marketed in multiple countries)","status":"marketed"},{"name":"TTVA","genericName":"TTVA","slug":"ttva","indication":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus","status":"phase_3"},{"name":"mRNA vaccine BNT162b2 (Pfizer)","genericName":"mRNA vaccine BNT162b2 (Pfizer)","slug":"mrna-vaccine-bnt162b2-pfizer","indication":"COVID-19 prevention in individuals 6 months of age and older","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"batch 2 of MCV4","genericName":"batch 2 of MCV4","slug":"batch-2-of-mcv4","indication":"Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y","status":"phase_3"},{"name":"batch 3 of MCV4","genericName":"batch 3 of MCV4","slug":"batch-3-of-mcv4","indication":"Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months through 55 years of age.","status":"phase_3"}]}],"pipeline":[{"name":"PCV13i","genericName":"PCV13i","slug":"pcv13i","phase":"phase_3","mechanism":"PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.","indications":["Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F"],"catalyst":""},{"name":"TT","genericName":"TT","slug":"tt","phase":"marketed","mechanism":"TT is a recombinant adenovirus type 5 vector-based vaccine that expresses the SARS-CoV-2 spike protein to elicit immune responses against COVID-19.","indications":["COVID-19 prevention (marketed in multiple countries)"],"catalyst":""},{"name":"ChAdOx1-VZV","genericName":"ChAdOx1-VZV","slug":"chadox1-vzv","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DTcP","genericName":"DTcP","slug":"dtcp","phase":"phase_3","mechanism":"DTcP is a recombinant protein subunit vaccine that stimulates immune responses against diphtheria, tetanus, and pertussis antigens.","indications":["Prevention of diphtheria, tetanus, and pertussis in pediatric and adult populations"],"catalyst":""},{"name":"MCV4","genericName":"MCV4","slug":"mcv4","phase":"marketed","mechanism":"MCV4 is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"],"catalyst":""},{"name":"MPSV4","genericName":"MPSV4","slug":"mpsv4","phase":"phase_3","mechanism":"MPSV4 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"],"catalyst":""},{"name":"MSPV4","genericName":"MSPV4","slug":"mspv4","phase":"phase_3","mechanism":"MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups.","indications":["Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y"],"catalyst":""},{"name":"Placebo for Inhalation","genericName":"Placebo for Inhalation","slug":"placebo-for-inhalation","phase":"marketed","mechanism":"A placebo inhalation formulation that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"TTVA","genericName":"TTVA","slug":"ttva","phase":"phase_3","mechanism":"TTVA is a vaccine that induces an immune response against the SARS-CoV-2 virus.","indications":["Prevention of COVID-19 disease caused by SARS-CoV-2 virus"],"catalyst":""},{"name":"batch 2 of MCV4","genericName":"batch 2 of MCV4","slug":"batch-2-of-mcv4","phase":"phase_3","mechanism":"MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.","indications":["Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y"],"catalyst":""},{"name":"batch 3 of MCV4","genericName":"batch 3 of MCV4","slug":"batch-3-of-mcv4","phase":"phase_3","mechanism":"MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.","indications":["Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months through 55 years of age."],"catalyst":""},{"name":"mRNA vaccine BNT162b2 (Pfizer)","genericName":"mRNA vaccine BNT162b2 (Pfizer)","slug":"mrna-vaccine-bnt162b2-pfizer","phase":"phase_3","mechanism":"BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.","indications":["COVID-19 prevention in individuals 6 months of age and older","COVID-19 booster vaccination"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMVFadE9yTEswTTRJZ1dtOWRmcGY2RDNBbzJfRnNkcHptVTdhXzloTG55Q2gtVW9WYkVKemdzSVJ0VktybGFoZEg1RFhvQ2ViMDFUY2VxYVdLbFhxRmViTmE5OFI1akRzaFdLcU5ZUGxaS3pEcU13QUNMTFNXY3UydExEaXVLVzQy?oc=5","date":"2024-12-23","type":"pipeline","source":"Pharmaceutical Technology","summary":"SK bioscience and Sanofi expand agreement for PCVs - Pharmaceutical Technology","headline":"SK bioscience and Sanofi expand agreement for PCVs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQZDZqNjlYOHFJSWpDX2JNRmt0ZnV2UWx0elUzaU1vc1JJbXprRmE4U2thYXNzUFJXdUR5TlVxdlN0X0FkTmpxY3dpVlRMRkdvTE5Tc0NDRmh5bXNWSy1sS3d4U1RvTVprNDdnTGZzQ2ZiZXpIbkhweWN4QlNxQXBhNE1mOUxvTGVNemk5SE1RU0xPanJLZkhOZHREQ2hlMm8xaWgyckZJNmxzdXpZ?oc=5","date":"2023-09-05","type":"deal","source":"Fierce Pharma","summary":"After AstraZeneca mRNA deal, CanSino eyes other production partnerships: Reuters - Fierce Pharma","headline":"After AstraZeneca mRNA deal, CanSino eyes other production partnerships: Reuters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxONmwwUzJsMG1ieWxzTFpNd1FJZ25mdzF6VmRkSURSR0ZUckRaSm1XMDZBYzhBN0V6dmhEQkpBZEt0b3Y2WUlxVV9KV2dnVFJWQmhzbTZIc3lkcEd6NWkyNmRlVE91d0JKZ2xNQk9FUTBaV0hXVnh5dU5iQ1EyM1BGcGc2amhYUnM5NmMtWDNyMlVEd1hkV1hGU2dfVXh5Q2xHSWxuTGhsQm1BWWxMVmVjaWpZcU5yLW52RGEwc0drVmJENjVXOExnZEMyYURuaTNLb2k4?oc=5","date":"2023-08-31","type":"deal","source":"reuters.com","summary":"China's CanSino seeks more vaccine contracts after AstraZenca deal - reuters.com","headline":"China's CanSino seeks more vaccine contracts after AstraZenca deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxONHIyRFFTUUw1WUtjX3V5X1VQNjN2MlpneFR1RzZDWEc3UHlETEY4M1g0YTVTT3BmTXRfcU4yZ1JJWWthVEMyaVZ5SUpVQl9XUFo1b1pSOHNQSUlpUkFvSmpIYXZvYkhObDd1LWJwUHhHSWE1TXZLRkhiWDFCVkFJMXIyejJaUllIblpmY0tXREFkalZlMHBSdDFLcUxRR3JNaFEzUTB3NFoxTzZ3dlQzRjUxekl2SW10ajZTdHVR?oc=5","date":"2023-08-09","type":"deal","source":"reuters.com","summary":"China's CanSino in mRNA vaccine deal with AstraZeneca - reuters.com","headline":"China's CanSino in mRNA vaccine deal with AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaHpSOFlpdU9BU0xtNlA4YU5LLUJXQzNvTXF6c1poTkdXV1lZOEZDNnFsYzVIMlpTT2tndzhYSF9OZmZLanc2Y29fR0NmX1d3TVotb2ZvU2QyQkdpdXlZcGJQNWVRR3pBVzZqd0xVYnZRMFpyZ3EySGVnbEtmMjJneUhRNTNUTmcxRXNIUms3UC1OU0FCei05NnZEVVQxenVXdXRPaDMyVXRaR03SAbABQVVfeXFMTjlvZ1lYWVNqSXFpb0ZyYzktWFdXNGY0RkluNkhUb1BuV1NUeDRsWC1Gc0Foc0sxNWpIZFNkay1McHVCd1J0WkQ1c0F3WjlMV3U5OWV5Z3pLS1IyNGpscEZYQlF1LUtRSWdGVVpLcDBEWjBkcHdvQ0dmbFFMWi15S1NkckpZampaZW1XNE9wZTdSWE9OdEFiRGhyc0E2UUo2NmdlUzFsdGFYeWNNR09tM3g?oc=5","date":"2022-09-04","type":"regulatory","source":"CNBC","summary":"CanSino's inhaled Covid-19 vaccine gets emergency use approval in China - CNBC","headline":"CanSino's inhaled Covid-19 vaccine gets emergency use approval in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPT1RacTB1TjBoTWx4Y2k5U1lXWUYxZzBvUGlKRW02RTdFeWJGRFlOVmFZYjJiMU5CM25vcVdxSDZMSWZqREV3WkVwWmxjaXJVc3prckxKdHJhUEYxTVowSlBkUC1zZmtLMHRPbEJ0MlRCSTFuVlNQajBsTXRUZFVNOVByRjdjejFHZS16VDQ4QWZGd1kxUjVYSm9MMkduRjQwMnJuUWJsR1c2OG5xbDU2MFUzSEdoQQ?oc=5","date":"2022-09-04","type":"regulatory","source":"reuters.com","summary":"CanSino's inhaled COVID-19 vaccine gets emergency use approval in China - reuters.com","headline":"CanSino's inhaled COVID-19 vaccine gets emergency use approval in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQS0EyTE84ZDBya0RhUFRLcTNKNUdudGg1aDJNRTM4Z2RjTENhZlJiRGNXQktyOXFCMDc4YVRhSjgxVWNmNTBjdTNKMm8tUVUyMk5JVUUzRTlCRmRxNVF3M19KU0FaUjZYcmdXV0FydXd1T2ZRYi1qM3g1Ulk1UXpSSEN6YmRYY1ZJZ2ZpdWRn?oc=5","date":"2022-08-02","type":"pipeline","source":"启明创投","summary":"Qiming Monthly Newsletter (November 2021 - January 2022) - 启明创投","headline":"Qiming Monthly Newsletter (November 2021 - January 2022) - 启明创投","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPOVE1VFBONllseUlEVm5xbGVydENITDV4Nk9VSlVGZW1aVmhfTlBvOW40QTQ4WnFYS1FfZUk0U3JSSWlOWE9LcWsydGdzYmZRMWVUNkxFZmJJOU9XcVkxdkxmZGo3d213VnZ6VGlJT04xUXNMdE1udUhQVE9uRnFiOW55bkZZN3FEQ3lDbXptVFJuX3dFak40azlTcm1RQ21yYVNTU2U4UUhkdUZVejZjSTdwd2g4ZW13ZTFtOHh4TEtmVTNzalZiRDE2cS1xMFdIVkZXX29oZERmR1BWSldBSg?oc=5","date":"2021-12-23","type":"trial","source":"reuters.com","summary":"China CanSinoBIO's vaccine 57.5% effective against COVID in Phase III trial-study - reuters.com","headline":"China CanSinoBIO's vaccine 57.5% effective against COVID in Phase III trial-study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPOVdWZVQyMXlwSTN6eTBLVUtUUDBQRjB6cHptZzhNekZNNXFxNkVudW00VmhMOXNyZVFPcWw1VU43YkJqczczQTFVa0djMXM5V3hKU1lPUWlSNHJXcE0zWU10WnpUdXh1alFMcUtzUUh2eV9YYnNXWHF6UXNyNEJUcmhyc0ZSOXhhc2pkT0w4d28tYWhvQ1RUNTR5czRMUHdjVDBfajlWekFJeXRxaXR2VlNLcTRlTGJQVWU1VUM1R0FnM0xBWUJSVXIxRGRCY05WNkxOT1d4ajg?oc=5","date":"2021-08-27","type":"earnings","source":"reuters.com","summary":"COVID shot drives CanSinoBIO's first six-month profit since at least 2019 - reuters.com","headline":"COVID shot drives CanSinoBIO's first six-month profit since at least 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOcmpGdVkxMmp1RGQxbXdHMzBJTExHUkxJQ0VUazJLc21VS0ZWUVZYSmlvaTBKcFI5TUh4a1l3LVBhX2FhaTJxeHY4RlJnWnlTaGYwRVBfY3JkejItWGNOYlUtZ2RxLWhJNnc0RUtPMk1taHRhNjNyTENJZkg4cVFQTHFKMm14THdpaTBabTEzUXQzVTdEQzdNZ1RXZk91dEJXcDRELWJpeGJRMmVkNGhRN0RkQ0NBOHJVbVNuag?oc=5","date":"2021-06-09","type":"trial","source":"reuters.com","summary":"China to study using CanSinoBIO COVID shots as a booster - reuters.com","headline":"China to study using CanSinoBIO COVID shots as a booster","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQekFpcmNIVUtoWkduV3dqT1RVR25XVG9IQkVUZzZPcVAzZThrckZrNXRDSndaSTRmNXhvanFQTGIxQktQUS1YQi13UC0tR09rRG9xOHplaTJCSVpBVzN2dzdpNWZzejRZMlA0Z2x5Y2JLWnVrcXlZZWRXdlFCazZXbHhuWmhZZDMyVEptYzVWU0dURUhROEZYRUY3TUlJVTBYZXo5N19ZOFBCYW1MWjlRWm5BVWZVdTk5alE?oc=5","date":"2020-08-13","type":"pipeline","source":"BioPharma Dive","summary":"CanSino rides coronavirus vaccine progress to lucrative Shanghai market debut - BioPharma Dive","headline":"CanSino rides coronavirus vaccine progress to lucrative Shanghai market debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSTZYRFFoRTh6bzEwMFpDMk02eURRM3g1b1ljMldEem80WFVCcmRBZmNKdFYyTGJhSXVVN3JrMHQ5R3FnWmhXTHo5ckFGblltVHpLN1ZaQkVidTBIcFltUjQ0Rk9mT3pYdXVQRk9xTmVXUXhVOEFmZTlWVzBVbUNaNEpqb0FpdzJmQlR4QjNEQ0NTVHVVY0xrZ3hTTE0yQlUyYlRyajZ3dXhONUk?oc=5","date":"2020-04-13","type":"deal","source":"World Health Organization (WHO)","summary":"Public statement for collaboration on COVID-19 vaccine development - World Health Organization (WHO)","headline":"Public statement for collaboration on COVID-19 vaccine development - World Health Organization (WHO)","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":8,"marketed":3,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}